Comparing Lookback Periods to Ascertain Alzheimer's Disease and Related Dementias.

IF 2.7 4区医学 Q2 CLINICAL NEUROLOGY

American Journal of Alzheimers Disease and Other Dementias Pub Date : 2023-01-01 DOI:10.1177/15333175231199566

Zachary J Kunicki, Thomas Bayer, Lan Jiang, Melanie L Bozzay, McKenzie J Quinn, Alyssa N De Vito, Sheina Emrani, Sebhat Erqou, John E McGeary, Andrew R Zullo, Matthew S Duprey, Mriganka Singh, Jennifer M Primack, Catherine M Kelso, Wen-Chih Wu, James L Rudolph

{"title":"Comparing Lookback Periods to Ascertain Alzheimer's Disease and Related Dementias.","authors":"Zachary J Kunicki, Thomas Bayer, Lan Jiang, Melanie L Bozzay, McKenzie J Quinn, Alyssa N De Vito, Sheina Emrani, Sebhat Erqou, John E McGeary, Andrew R Zullo, Matthew S Duprey, Mriganka Singh, Jennifer M Primack, Catherine M Kelso, Wen-Chih Wu, James L Rudolph","doi":"10.1177/15333175231199566","DOIUrl":null,"url":null,"abstract":"<p><p>Claims data are a valuable resource for studying Alzheimer's disease and related dementias (ADRD). Alzheimer's disease and related dementias is often identified using a list of claims codes and a fixed lookback period of 3 years of data. However, a 1-year lookback or an approach using all-available lookback data could be beneficial based on different research questions. Thus, the purpose of this study was to compare 1-year and all-available lookback approaches to ascertaining ADRD compared to the standard 3-year approach. Using a cohort of Veterans hospitalized for heart failure (N = 373, 897), our results suggested high agreement (93% or greater) between the lookback periods. The 1-year lookback period had lower sensitivity (60%) and underestimated the prevalence of ADRD. These results suggest that 1-year and all-available lookback periods are viable approaches when using claims data.</p>","PeriodicalId":50816,"journal":{"name":"American Journal of Alzheimers Disease and Other Dementias","volume":"38 ","pages":"15333175231199566"},"PeriodicalIF":2.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623942/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Alzheimers Disease and Other Dementias","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15333175231199566","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Claims data are a valuable resource for studying Alzheimer's disease and related dementias (ADRD). Alzheimer's disease and related dementias is often identified using a list of claims codes and a fixed lookback period of 3 years of data. However, a 1-year lookback or an approach using all-available lookback data could be beneficial based on different research questions. Thus, the purpose of this study was to compare 1-year and all-available lookback approaches to ascertaining ADRD compared to the standard 3-year approach. Using a cohort of Veterans hospitalized for heart failure (N = 373, 897), our results suggested high agreement (93% or greater) between the lookback periods. The 1-year lookback period had lower sensitivity (60%) and underestimated the prevalence of ADRD. These results suggest that 1-year and all-available lookback periods are viable approaches when using claims data.

查看原文本刊更多论文

将回顾期与确定阿尔茨海默病和相关痴呆症进行比较。

索赔数据是研究阿尔茨海默病和相关痴呆（ADRD）的宝贵资源。阿尔茨海默病和相关痴呆症通常通过索赔代码列表和3年的固定数据回顾期来识别。然而，基于不同的研究问题，一年的回顾或使用所有可用的回顾数据的方法可能是有益的。因此，本研究的目的是将确定ADRD的1年和所有可用的回顾方法与标准的3年方法进行比较。使用一组因心力衰竭住院的退伍军人（N=373897），我们的结果表明，回顾期之间的一致性很高（93%或更高）。1年回顾期的敏感性较低（60%），低估了ADRD的患病率。这些结果表明，在使用索赔数据时，1年和所有可用的回顾期是可行的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Alzheimers Disease and Other Dementias GERIATRICS & GERONTOLOGY-CLINICAL NEUROLOGY

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： American Journal of Alzheimer''s Disease and other Dementias® (AJADD) is for professionals on the frontlines of Alzheimer''s care, dementia, and clinical depression--especially physicians, nurses, psychiatrists, administrators, and other healthcare specialists who manage patients with dementias and their families. This journal is a member of the Committee on Publication Ethics (COPE).